गुजरात थेमिस बायोसिन शेअर किंमत

Please refer to our investors presentation for the quarter ended 30.06.2026

• बीएसई इंडिया
• 9 तास 14 मिनिटांपूर्वी

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Gujarat Themis Biosyn announced Q1FY27 results</strong></span></h3><p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">स्टँडअलोन फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Income from Operations:</strong> The company reported Rs 4,379.00 lakh in Q1FY27, representing a YoY increase of 22.07% compared to Rs 3,587.28 lakh in Q1FY26. On a QoQ basis, it saw a slight decrease of 1.00% from Rs 4,423.30 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Total Income:</strong> Standalone total income for Q1FY27 stood at Rs 4,392.16 lakh, marking a YoY growth of 21.51% from Rs 3,614.72 lakh in Q1FY26 and a QoQ decline of 2.73% from Rs 4,515.41 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Profit Before Tax:</strong> The company achieved a profit before tax of Rs 1,516.53 lakh in Q1FY27, an increase of 25.13% YoY from Rs 1,211.96 lakh in Q1FY26. It recorded a QoQ growth of 5.78% from Rs 1,433.65 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Net Profit After Tax:</strong> Standalone net profit for the quarter was Rs 1,106.67 lakh, reflecting a YoY growth of 22.13% from Rs 906.16 lakh in Q1FY26 and a QoQ increase of 1.61% from Rs 1,089.12 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Total Comprehensive Income:</strong> This was recorded at Rs 1,106.80 lakh in Q1FY27 compared to Rs 907.44 lakh in Q1FY26 and Rs 1,089.54 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Earnings Per Share (EPS):</strong> Basic and Diluted EPS for Q1FY27 stood at Rs 1.02, compared to Rs 0.83 in Q1FY26 and Rs 1.00 in Q4FY26.</li></ul><p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">एकत्रित फायनान्शियल हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Income from Operations:</strong> Consolidated revenue for Q1FY27 was Rs 4,379.00 lakh, an increase of 22.07% YoY from Rs 3,587.28 lakh in Q1FY26 and a 1.00% decrease QoQ from Rs 4,423.30 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Total Income:</strong> Total consolidated income reached Rs 4,392.16 lakh in Q1FY27, up 21.51% YoY from Rs 3,614.72 lakh in Q1FY26 and down 2.73% QoQ from Rs 4,515.41 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Net Profit After Tax:</strong> Net profit for the period stood at Rs 1,106.67 lakh in Q1FY27, marking a YoY growth of 22.13% from Rs 906.16 lakh in Q1FY26 and a QoQ increase of 1.61% from Rs 1,089.12 lakh in Q4FY26.</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Total Comprehensive Income:</strong> The company reported Rs 1,106.80 lakh in Q1FY27, compared to Rs 907.44 lakh in Q1FY26 and Rs 1,089.54 lakh in Q4FY26.</li></ul><p _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">बिझनेस हायलाईट्स:</strong></p><ul><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Segment Performance:</strong> As per the company commentary, "The Company operates only in one Business Segment i.e. manufacturing of fermentation-based pharmaceutical intermediates and APIs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 'Operating Segments'."</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Subsidiary Incorporation:</strong> During Q1FY27, the company incorporated two wholly-owned subsidiaries outside India: Themis Biosyn Japan Limited (Japan) and Themis Biosyn Ireland Private Limited (Ireland).</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Operational Status of Subsidiaries:</strong> As noted in the results, "The subsidiaries have been consolidated from the respective dates on which control was obtained in accordance with Ind AS 110 'Consolidated Financial Statements'. As the entities are yet to commence operations and no capital has been remitted, there is no impact on the consolidated financial results."</li><li _ngcontent-ng-c2478508423=""><strong _ngcontent-ng-c2478508423="">Comparative Reporting:</strong> This is the first quarter in which the company has prepared consolidated financial results. Consequently, the comparative financial information for Q1FY26 and Q4FY26 is identical to the standalone financial information previously reported.</li></ul><p><a class="lb" href="/marathi/get-document/post/pdf/5771766/" target="_blank">रिझल्ट PDF</a></p>

• ट्रेंडलाईन
• 10 तास 18 मिनिटांपूर्वी

Please refer to the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June ,2026

• बीएसई इंडिया
• 11 तास 21 मिनिटांपूर्वी